High Assay Pharmaceutical Raw Material API Peptide Atosiban Acetate CAS 90779-69-4

• CAS No.: 90779-69-4
• Formula: C45h71n11o14s2
• EINECS: 806-815-5
• Environmental Protection: Yes
• Certification: ISO
• Color: White
• Model NO.: powder
• Classification: Peptide
• Function: Keeping Health and Promoting Growth
• Appearance: Powder
• Transport Package: 10g/Al Bag
• Specification: 99%
• Trademark: Huadi
• Origin: China
• Production Capacity: 10000g/Month

Product Description

Atosiban Acetate is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor.
Atosiban is a synthetic peptide oxytocin antagonist. It binds to membrane bound oxytocin receptors on the myometrium and prevents oxytocin-stimulated increases in inositol triphosphate production. This prevents release of stored calcium from the sarcoplasmic reticulum and subsequent opening of voltage gated calcium channels. This shutdown of cytosolic calcium increase prevents contractions of the uterine muscle, reducing the frequency of contractions and inducing uterine quiescence.
Huadi Group is a national high-tech enterprise. It is invested and established by a group of professionals who are specialized in the R&D of the biopharmaceutical field and have rich experience in production management and operation. It is a group company that invests in the production of diversified industries such as pharmaceuticals, medical devices, food, health products, cosmetics, and biological agriculture products.

Huadi Group has a total of 8 subsidiaries: Zhejiang Huadi Pharmaceutical Group Co., Ltd., Hangzhou Huajin Pharmaceutical Co., Ltd., Zhejiang Huajun Pharmaceutical Co., Ltd., Zhejiang Huadi Pharmaceutical Group Pharmaceutical Development Co., Ltd., Hangzhou Huadi Health Technology Co., Ltd., Leizhou Huadi Biotechnology Co., Ltd., Hainan Huadi Pharmaceutical Co., Ltd., Hunan Huadi Biotechnology Co., Ltd.

Huadi Group is the vice president unit of the China Biochemical Pharmaceutical Industry Association and the vice president unit of the Zhejiang Health Industry Research Association. Its controlling subsidiary, Zhejiang Huadi Pharmaceutical Group, is the drafting unit of the GMP appendix for biochemical drugs of the National Good Manufacturing Practice for Drugs. The group has two provincial-level R&D centers, the Chief Scientist is a senior scientist and overseas returnee PhD from a fortune 500 company in the United States. The company has long hired domestic and foreign experts and scholars as technical consultants, with strong technological innovation capabilities. With nearly 30 years of R&D and industrial transformation experience in biochemical extraction products, multi-component biochemical drugs, and synthetic peptide products, the technical level is leading domestically; In 2019, the group jointly launched internationally leading biopharmaceutical cutting-edge projects with senior research teams from the United States and Zhejiang University: The preparation of medicinal proteins using plant instantaneous expression systems, and the personalized treatment of tumors - neoantigen peptide project. All of these projects have made breakthrough progress and their technical level is internationally leading.